REIMBURSEMENT AND CAPACITY IMPLICATIONS OF TRANSITIONING PATIENTS TO HOME-BASED SCIG IN SID AND CIDP: A PRACTICE-LEVEL ECONOMIC MODEL IN GERMANY
Author(s)
Batyrkhan Kuatov, MA1, Laurence UNDREINER, PhD2, Leonie Schumacher, MSc3, Caroline Rupprecht, MSc3, Nhu Ngoc Le, BS3, Florian Kron, PhD3, Thomas Hardt, PhD4.
1Director HEOR, Global Market Access, CSL Behring, Bern, Switzerland, 2CSL Behring, Paris, France, 3VITIS Healthcare Group, Cologne, Germany, 4CSL Vifor, Munich, Germany.
1Director HEOR, Global Market Access, CSL Behring, Bern, Switzerland, 2CSL Behring, Paris, France, 3VITIS Healthcare Group, Cologne, Germany, 4CSL Vifor, Munich, Germany.
OBJECTIVES: German outpatient infusion centers face increasing capacity constraints. Intravenous immunoglobulin (IVIg) infusions occupy infusion chair capacity otherwise available for other intravenous (IV) treatments. This study models scenarios in which eligible IVIg patients transition to home-based subcutaneous immunoglobulin (SCIg) therapy in Germany. SCIg may be simpler and quicker to administer, with the potential to reduce treatment burden in alignment with patient preferences. The analysis also evaluates the economic implications for healthcare providers and outpatient infusion centers.
METHODS: A deterministic outpatient provider cost model estimated the financial impact of IVIg to SCIg switching, assuming freed infusion capacity is reallocated to other IV therapies, with impact defined by differences in applicable reimbursement rates. In secondary immunodeficiencies (SID) and chronic inflammatory demyelinating polyneuropathy (CIDP), financial impact per IVIg-treated patient corresponds to €594 and €364 annually per patient, respectively. Reallocation of capacity to alternative IV therapies was associated with a higher financial impact per patient: €1,743 for hematology/oncology, €455 for rheumatology, and €432 for neurology.
RESULTS: In a hypothetical outpatient practice with 10 infusion chairs switching 5 patients from IVIg to SCIg improve chair capacity, in a SID scenario, reallocation to hematology/oncology therapies results in approximately €5,746 additional annual financial efficiency. In a CIDP scenario, reallocation of freed chairs to hematology/oncology generates an incremental annual financial efficiency of €6,893 for 5 patients, compared to €454 for rheumatology and €337 for neurology.
CONCLUSIONS: Given comparable efficacy of IVIg and SCIg, structured IVIg to SCIg transition improve capacity allocation by redirecting chair time to alternative IV care, with an increased financial benefit for German outpatient infusion practices and alignment with patient preference. Supporting practice-level resource planning, these programs help address healthcare resource constraints.
METHODS: A deterministic outpatient provider cost model estimated the financial impact of IVIg to SCIg switching, assuming freed infusion capacity is reallocated to other IV therapies, with impact defined by differences in applicable reimbursement rates. In secondary immunodeficiencies (SID) and chronic inflammatory demyelinating polyneuropathy (CIDP), financial impact per IVIg-treated patient corresponds to €594 and €364 annually per patient, respectively. Reallocation of capacity to alternative IV therapies was associated with a higher financial impact per patient: €1,743 for hematology/oncology, €455 for rheumatology, and €432 for neurology.
RESULTS: In a hypothetical outpatient practice with 10 infusion chairs switching 5 patients from IVIg to SCIg improve chair capacity, in a SID scenario, reallocation to hematology/oncology therapies results in approximately €5,746 additional annual financial efficiency. In a CIDP scenario, reallocation of freed chairs to hematology/oncology generates an incremental annual financial efficiency of €6,893 for 5 patients, compared to €454 for rheumatology and €337 for neurology.
CONCLUSIONS: Given comparable efficacy of IVIg and SCIg, structured IVIg to SCIg transition improve capacity allocation by redirecting chair time to alternative IV care, with an increased financial benefit for German outpatient infusion practices and alignment with patient preference. Supporting practice-level resource planning, these programs help address healthcare resource constraints.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE715
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Rare & Orphan Diseases